Drug Profile
Galectin 3C
Alternative Names: Gal-3C; Galectin-3CLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator MandalMed
- Developer MandalMed; Texas Tech University Health Sciences Center; University of California at San Francisco
- Class Antifibrotics; Galectins
- Mechanism of Action Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Cancer; Lymphoma
Highest Development Phases
- No development reported Breast cancer; Fibrosis; Lymphoma; Multiple myeloma
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Lymphoma in USA
- 28 Aug 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA (IM)
- 28 Aug 2018 No recent reports of development identified for research development in Fibrosis in USA